Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Opinion & analysis

Opinion & analysis


  • Sort by Custom
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Click to order products descending
  • Display 15 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page

  • Behind The Scenes Of Digital Health: Medtech Players And Partners

    $100.00

    The digitalization of health care has been much talked about over the last decade or so. But activity among the medical device manufacturers and service providers has only just recently accelerated as they start overcoming barriers and resistance to this new way of delivering health care.

    February 5, 2018
    Find out more

  • Bayer’s US Playbook: The Smart Way To Top-Line Growth

    $200.00

    Tap into Bayer AG’s plans to establish itself as a global innovator, particularly with their oncology, cardiovascular, and women’s health franchises. In this exclusive interview, In Vivo talks strategy with Dr. Carsten Brunn, Bayer’s Head of Pharmaceuticals, Americas Region.

    June 18, 2018
    Find out more

  • Bayer’s Consumer Chief Initiates Turnaround Plan In Bid To Return Troubled Business To Growth

    $200.00

    Bayer AG is seeking to turn around its troubled Consumer Health division through implementing key portfolio changes and embracing growth-focused innovation, according to Heiko Schipper, President of Consumer Health.  Find out what’s in store for Bayer AG’s Consumer Health group, straight from its top leadership.

    December 17, 2018
    Find out more

  • ASCO 2018: Optimism As Industry Resets And Looks To What Is Next

    $200.00

    The tone of the 2018 ASCO annual meeting was one of regrouping, resolve, and refinement that may have left investors apathetic, but signaled a commitment to getting it right going forward to those in pharma. Examine the key takeaways from ASCO 2018.

    June 4, 2018
    Find out more

  • As Humira Biosimilars Arrive, Battle Lines Shift From Education To Sustainability

    $200.00

    As a European wave of Humira biosimilars challenges the best-selling drug in the world, the question of how biosimilars will affect the market, from payers, to practitioners, to patients, comes to the forefront. Examine how biosimilars are poised to change the landscape as focus shifts from whether to adopt their use to how to actually use them effectively.

    October 15, 2018
    Find out more

  • Anti-Aging Cosmetics Or Unlawfully Marketed Drugs? Two Federal Court Cases To Watch

    $131.00

    Skin-firming and anti-wrinkle claims on products marketed as cosmetics are being tested in California federal course. The results will have considerable implications on the health, beauty and wellness industry. HBW looks at similarities and differences of the two cases.

    September 2, 2019
    Find out more

  • Annuity Payment Model For Cures May Get Test Drive In Massachusetts

    $131.00

    Commercial payers in Massachusetts and AveXis may soon pilot an annuity payment model for Zolgensma. This would spread out insurance payments for the high-cost treatment over years to reduce the burden on payers. The pilot will likely involve a performance component. Learn who the players are and what they stand to gain–and what they risk. Find out how the annuity model would work in practice.

    February 19, 2019
    Find out more

  • Analysts Weigh Up Benefits Of Big Bayer Restructuring

    $131.00

    The recent shakeup at Bayer AG took some observers by surprise, but was heralded by most as a much-needed measure to maintain the German giant’s viability. Find out how this restructuring will play out, and what top analysts make of the move to streamline the organization.

    November 30, 2018
    Find out more

  • An FDA Age-Based Predicate Policy Would Be Arbitrary, Reg Experts Complain

    $200.00

    The US FDA intends to make changes to its 501(k) process, and is currently considering a proposal to impose an age limitation on predicate devices as a means of encouraging the use of more modern predicates. Opponents of the plan argue that such a step would do little to achieve the FDAs goals in this area.

    April 18, 2019
    Find out more

  • Amarin CEO: Consumers Have Heard About Omega-3 Heart Benefits ‘Too Long’

    $200.00

    Amarin’s John Thero says the firm expects a jump in sales for Vascepa from potential label expansion allowing a larger patient groups with lower triglycerides than current label indications. At the same time, he notes competitors fail to show broader cardiovascular risk reduction.

    August 2, 2019
    Find out more

  • Amarin CEO Thero On Gearing Up For Success Ahead Of The Big Vascepa Ad Comm

    $131.00

    Speaking with Scrip recently, Amarin CEO, John Thero talked about the upcoming US advisory committee meeting for Vascepa and commercial expansion plans and deflected questions about a big pharma buyout. What he did say was that, “We’re planning for success.

    September 2, 2019
    Find out more

  • AHPA Backs NDI Filing For Kratom, Experts Question FDA Enforcement

    $200.00

    AHPA called on FDA to regulate kratom as an NDI to avoid a patchwork of state regulations. Kratom, used to manage opioid withdrawal, garnered unwelcome scrutiny after being linked to a salmonella outbreak. Will the FDA treat it like any other dietary ingredient? Find out what may lie ahead for this herbal extract.

    April 30, 2018
    Find out more

  • Adaptive Clinical Trial Designs: US FDA Provides Checklist To Begin Study

    $130.00

    On September 28, 2018, the US FDA issued new draft guidelines for adaptive clinical trial designs, as well as additional guidance updates. Tap into these important updates, which replace draft guidance issued by the agency in 2010.

    September 30, 2018
    Find out more

  • Accenture Prescribes A New Data Management Future For Medtechs

    $200.00

    In Vivo examines efforts by Accenture Life Sciences to survey medtech CEOs on their digital preparedness as leaders look to build new revenue streams from innovative business models by effectively managing data. Discover what trends they uncovered in this illuminating article from In Vivo.

    November 21, 2018
    Find out more

  • AbbVie’s Skyrizi Poised To Enter Packed Psoriasis Market

    $200.00

    AbbeVie is banking on the success of a possible simultaneous European/US launch of Skyrizi, its psoriasis drug, to bolster the company’s declining revenues in Europe. Read about how the company plans to use Skyrizi to bounce back from the genericization of its blockbuster Humira in this informative article.

    March 4, 2019
    Find out more
Page 19 of 20
Page 19 of 20«‹17181920›
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London, SW1P 1WG. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top